Author: Xiao Huang; Jasper Z. Williams; Ryan Chang; Zhongbo Li; Eric Gai; David M. Patterson; Yu Wei; Wendell A. Lim; Tejal A. Desai
Title: DNA-scaffolded biomaterials enable modular and tunable control of cell-based cancer immunotherapies Document date: 2019_3_23
ID: 5bw7umap_46
Snippet: The precise ratio of agonistic antibodies (anti-CD3 and anti-CD28) for T cell activation on AICE impacts ex vivo T expansion efficiency, as well as T cell differentiation and exhaustion phenotypes. The ability to accurately control the ratio of multi-cargo particle loading should enable identification of novel, precise combinations of modulatory signals that lead to diversified and improved T cell behavior. The use of biodegradable materials also.....
Document: The precise ratio of agonistic antibodies (anti-CD3 and anti-CD28) for T cell activation on AICE impacts ex vivo T expansion efficiency, as well as T cell differentiation and exhaustion phenotypes. The ability to accurately control the ratio of multi-cargo particle loading should enable identification of novel, precise combinations of modulatory signals that lead to diversified and improved T cell behavior. The use of biodegradable materials also omits the need for synthetic material removal prior to cell implantation. Cumulatively, these properties suggest that AICE could aid in manufacturing for ACT by improving the ease-of-production and fine-tuning the yield and phenotype of the therapeutic cell product.
Search related documents:
Co phrase search for related documents- cell product and therapeutic cell product: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date